Wei Zhang

Tan Tock Seng Hospital — Singapore

Medicine · Health Sciences

29h-index3.4kcitations146works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Urinary Bladder and Prostate Research(12), Glutathione Transferases and Polymorphisms(11), Receptor Mechanisms and Signaling(9), Pelvic floor disorders treatments(8), Chemical Synthesis and Analysis(8)

Publications145 total

Supplementary Figure S3 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S3 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Data from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases
Journal of Inflammation Research·2025Open Access
SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
Molecular Cancer Therapeutics·2025
SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Molecular Cancer Therapeutics·2025
[Genomic characterization of group A <i>Streptococcus</i> of different <i>emm</i>-type in Tianjin City from 2011 to 2024].
PubMed·2025
page 1 of 8Next →

Frequent Co-authors

Bengt Mannervik(6), Ilya Shmulevich(2), Arvind Rao(2), Vésteinn Thórsson(2), William M. Atkins(2), Yongchang Li(2), Huercha(2), Xinli Fan(2), Bayin Chahan(2), Olof Modén(2), Shuzhen Ping(2), Liang Li(2), Min Lin(2), Robert W. Colman(2), Joel Saltz(1), Rajarsi Gupta(1), Le Hou(1), Tahsin Kurç(1), Pankaj K. Singh(1), Vu Nguyen(1)